Latest News and Press Releases

– Closes Private Placement Financing of Up to $104.5 Million – Secures Orphan Drug Designations for QRX003 for Netherton Syndrome (NS) in the U.S. and Europe  – Advances Proposed Expedited...

FDA indicated that a single Phase 3 study may be sufficient to support marketing approval in the U.S. FDA expressed openness to an alternative study design for Phase 3 that would likely not include a...

ASHBURN, Va., March 19, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and...

— Fast Track Designation facilitates development and expedites regulatory review of therapies addressing serious conditions with significant unmet medical need — — QRX003 lotion (4%) currently being...

NETHERTON NOW Recognizes Rare Disease Day and Highlights Growing Global Awareness of Netherton Syndrome

Confirmation Received from MHLW That QRX003 Qualifies for Both Orphan Drug Designation and Fast Track Regulatory Review Status Quoin Initiating the Establishment of a Japanese Subsidiary to...

Target Loadings of 4% and 5% Rapamycin Achieved for Topical Lotion and Dermal Patch Delivery Technologies Respectively Clinical Trial and Stability Batch Manufacture to Commence in Q4 2025 Clinical...

– Private Placement Financing of Up to $105.3 Million Closed in October 2025 to Fund Operations and R&D – Sally Lawlor Appointed CFO to Support Commercialization and Financial Operations –...

ASHBURN, Va., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and...

Recruitment of Three Additional Pediatric Patients in Austria and Ireland Achieves Investigator Study TargetCurrent Pediatric Patient in Ongoing Study Has Completely Healed Skin After 9 months of...